165 related articles for article (PubMed ID: 28476816)
1. Diagnostic Performance of a Novel Multiplex Immunoassay in Colorectal Cancer.
Dressen K; Hermann N; Manekeller S; Walgenbach-Bruenagel G; Schildberg FA; Hettwer K; Uhlig S; Kalff JC; Hartmann G; Holdenrieder S
Anticancer Res; 2017 May; 37(5):2477-2486. PubMed ID: 28476816
[TBL] [Abstract][Full Text] [Related]
2. Cytokeratin serum biomarkers in patients with colorectal cancer.
Holdenrieder S; Stieber P; Liska V; Treska V; Topolcan O; Dreslerova J; Matejka VM; Finek J; Holubec L
Anticancer Res; 2012 May; 32(5):1971-6. PubMed ID: 22593474
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic relevance of a novel multiplex immunoassay panel in breast cancer.
Hermann N; Dressen K; Schroeder L; Debald M; Schildberg FA; Walgenbach-Bruenagel G; Hettwer K; Uhlig S; Kuhn W; Hartmann G; Holdenrieder S
Tumour Biol; 2017 Jun; 39(6):1010428317711381. PubMed ID: 28618926
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of carcinoembryonic antigen and carcinoma antigen 19-9 for colorectal carcinoma.
Zhang SY; Lin M; Zhang HB
Int J Clin Exp Pathol; 2015; 8(8):9404-9. PubMed ID: 26464695
[TBL] [Abstract][Full Text] [Related]
5. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of carcinoembryonic antigen (CEA), epidermal growth factor receptor (EGFR), epithelial cell adhesion molecule EpCAM (GA733-2), and carbohydrate antigen 19-9 (CA 19-9) levels in colorectal cancer patients and correlation with clinicopathological characteristics.
Mourtzikou A; Stamouli M; Kroupis C; Christodoulou S; Skondra M; Kastania A; Pectasides D; Athanasas G; Dimas C
Clin Lab; 2012; 58(5-6):441-8. PubMed ID: 22783573
[TBL] [Abstract][Full Text] [Related]
7. Preliminary evaluation of clinical utility of CYFRA 21-1, CA 72-4, NSE, CA19-9 and CEA in stomach cancer.
Gwak HK; Lee JH; Park SG
Asian Pac J Cancer Prev; 2014; 15(12):4933-8. PubMed ID: 24998567
[TBL] [Abstract][Full Text] [Related]
8. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of CYFRA 21-1 as a serum biomarker for the detection of colorectal adenoma and advanced colorectal adenoma in people over the age of 45.
Lim DH; Lee JH; Kim JW
J Clin Lab Anal; 2018 Jan; 32(1):. PubMed ID: 28186354
[TBL] [Abstract][Full Text] [Related]
10. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.
Di Gioia D; Blankenburg I; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2016 Oct; 461():1-7. PubMed ID: 27451906
[TBL] [Abstract][Full Text] [Related]
11. A system for tumor heterogeneity evaluation and diagnosis based on tumor markers measured routinely in the laboratory.
Hui L; Rixv L; Xiuying Z
Clin Biochem; 2015 Dec; 48(18):1241-5. PubMed ID: 26216289
[TBL] [Abstract][Full Text] [Related]
12. Measurement of serum carcinoembryonic antigen, carbohydrate antigen 19-9, cytokeratin-19 fragment and matrix metalloproteinase-7 for detecting cholangiocarcinoma: a preliminary case-control study.
Lumachi F; Lo Re G; Tozzoli R; D'Aurizio F; Facomer F; Chiara GB; Basso SM
Anticancer Res; 2014 Nov; 34(11):6663-7. PubMed ID: 25368272
[TBL] [Abstract][Full Text] [Related]
13. Reference limits for chromogranin A, CYFRA 21-1, CA 125, CA 19-9 and carcinoembryonic antigen in patients with chronic kidney disease.
Mikkelsen G; Åsberg A; Hultström ME; Aasarød K; Hov GG
Int J Biol Markers; 2017 Oct; 32(4):e461-e466. PubMed ID: 28561881
[TBL] [Abstract][Full Text] [Related]
14. Serum CYFRA 21-1 in Biliary Tract Cancers: A Reliable Biomarker for Gallbladder Carcinoma and Intrahepatic Cholangiocarcinoma.
Huang L; Chen W; Liang P; Hu W; Zhang K; Shen S; Chen J; Zhang Z; Chen B; Han Y; Meng F; DeMorrow S; Yin X; Lai J; Liang L
Dig Dis Sci; 2015 May; 60(5):1273-83. PubMed ID: 25487191
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples.
Thomas DS; Fourkala EO; Apostolidou S; Gunu R; Ryan A; Jacobs I; Menon U; Alderton W; Gentry-Maharaj A; Timms JF
Br J Cancer; 2015 Jul; 113(2):268-74. PubMed ID: 26035703
[TBL] [Abstract][Full Text] [Related]
16. Clinical Performance of CEA, CA19-9, CA15-3, CA125 and AFP in Gastrointestinal Cancer Using LOCI™-based Assays.
Dolscheid-Pommerich RC; Manekeller S; Walgenbach-Brünagel G; Kalff JC; Hartmann G; Wagner BS; Holdenrieder S
Anticancer Res; 2017 Jan; 37(1):353-359. PubMed ID: 28011514
[TBL] [Abstract][Full Text] [Related]
17. Stem cell factor (SCF) and interleukin 3 (IL-3) in the sera of patients with colorectal cancer.
Mroczko B; Szmitkowski M; Wereszczyńska-Siemiatkowska U; Okulczyk B
Dig Dis Sci; 2005 Jun; 50(6):1019-24. PubMed ID: 15986847
[TBL] [Abstract][Full Text] [Related]
18. Toward standardized high-throughput serum diagnostics: multiplex-protein array identifies IL-8 and VEGF as serum markers for colon cancer.
Bünger S; Haug U; Kelly FM; Klempt-Giessing K; Cartwright A; Posorski N; Dibbelt L; Fitzgerald SP; Bruch HP; Roblick UJ; von Eggeling F; Brenner H; Habermann JK;
J Biomol Screen; 2011 Oct; 16(9):1018-26. PubMed ID: 21807963
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis.
Feng M; Zhu J; Liang L; Zeng N; Wu Y; Wan C; Shen Y; Wen F
Int J Clin Oncol; 2017 Apr; 22(2):283-290. PubMed ID: 27990560
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature.
Shitrit D; Zingerman B; Shitrit AB; Shlomi D; Kramer MR
Oncologist; 2005 Aug; 10(7):501-7. PubMed ID: 16079317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]